Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Brenda Clemens

Nurse Practitioner Palm Bay, FL Nurse Practitioner

NPI 1740232230 CMS profile 10777950

1326 Malabar Rd Se Ste 3, Palm Bay, FL 32907

Open in the dashboard

General payments

$5,872

255 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Brenda Clemens of Palm Bay, FL is reported in the CMS Open Payments database as having received $5,872 across 255 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 94th percentile of Nurse Practitioner profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $145 3
2024 General $1,594 53
2023 General $1,660 83
2022 General $1,312 64
2021 General $1,159 52

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Brenda Clemens
  • Nurse Practitioner median
  • Middle half of Nurse Practitioner
  • National median

In program year 2025, general payments to Brenda Clemens were reported at $145. Among 41,044 Nurse Practitioner profiles paid that year, the median was $174 and the middle half received between $55 and $557.

Show as a table
Year Brenda Clemens Nurse Practitioner median Middle half National median
2019 $0 $50 $22–$97 $163
2020 $0 $40 $16–$108 $114
2021 $1,159 $135 $40–$426 $132
2022 $1,312 $152 $48–$470 $149
2023 $1,660 $166 $54–$529 $160
2024 $1,594 $173 $55–$556 $164
2025 $145 $174 $55–$557 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Novo Nordisk Inc $708 26 payments
  2. Medtronic, Inc. $616 10 payments
  3. Sanofi-Aventis U.S. LLC $500 26 payments
  4. Radius Health, Inc. $438 20 payments
  5. Lilly USA, LLC $409 20 payments
  6. AbbVie, Inc. $357 19 payments
  7. AstraZeneca Pharmaceuticals LP $316 12 payments
  8. Abbott Laboratories $291 18 payments
  9. Amgen Inc. $271 9 payments
  10. Xeris Pharmaceuticals, Inc. $241 12 payments
  11. Other $1,726 83 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,515 251 payments
  2. Travel and Lodging $333 2 payments
  3. Education $23 2 payments
Products named General payments · program years 2021–2025
  1. MINIMED 780G $468 6 payments
  2. RYBELSUS $411 20 payments
  3. Ozempic $310 20 payments
  4. SYNTHROID $303 16 payments
  5. FARXIGA $272 10 payments
  6. SOLIQUA 100/33 $258 14 payments
  7. Tymlos Endocrinology $227 10 payments
  8. EVENITY $224 7 payments
  9. Tymlos Endocrinology $211 10 payments
  10. AFREZZA $199 10 payments
  11. Other $3,768 188 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 40 drugs

Part D claims

2,052

Median for Nurse Practitioner: 389

Drug cost

$1,338,778

Median for Nurse Practitioner: $21,885

Branded share of claims

77.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 250 $397,175
Trulicity Dulaglutide Brand 102 $144,587
Farxiga Dapagliflozin Propanediol Brand 151 $144,115
Jardiance Empagliflozin Brand 91 $118,735
Synjardy Xr Empagliflozin/Metformin Hcl Brand 104 $109,971
Xigduo Xr Dapaglifloz Propaned/Metformin Brand 80 $92,163
Mounjaro Tirzepatide Brand 47 $68,762
Toujeo Max Solostar Insulin Glargine,hum.Rec.Anlog Brand 33 $41,695
Tresiba Flextouch U-200 Insulin Degludec Brand 29 $38,108
Rybelsus Semaglutide Brand 19 $28,161

The 10 drugs with the highest cost, of 40 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
EVENITY
  • Amgen Inc. $127
$127 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $125
$125 — —
Tymlos
  • Radius Health, Inc. $120
$120 — —
SYNTHROID
  • AbbVie, Inc. $99
$99 73 —
Ozempic
  • Novo Nordisk Inc $73
$73 250 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

255 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record